FDA Confirms Paragraph IV Patent Challenge of Horizant 22399 (Gabapentin Enacarbil) for Extended-release Tablets 300 mg and 600 mg
Xenoport Inc said it would stop developing on its own a drug that showed high rates of side effects in a study and instead focus on its treatment for restless leg syndrome.nnThe company also said on Thursday that Ronald Barrett, its chief executive since 2001, has stepped down and will be succeeded by Chief Operating Officer Vincent Angotti.